Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3657776 | 1.00 | HTR2A (0.34) | HTR2AKIF11SMN1; SMN2SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL3203244 | 0.87 | KIF11 (0.32) | HTR2AKIF11DPP4DPP7 | |
| SCHEMBL13010782 | 0.76 | SMN1; SMN2 (0.38) | HTR2ASMN1; SMN2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9962947 | 0.74 | SIGMAR1 (0.37) | SMN1; SMN2SLC6A2SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL3194342 | 0.72 | HTR2A (0.33) | HTR2AKIF11 | |
| SCHEMBL3779463 | 0.71 | DPP4 (0.33) | SLC6A3DPP4 | |
| SCHEMBL1902599 | 0.69 | SMN1; SMN2 (0.43) | HTR2ASMN1; SMN2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3192627 | 0.68 | SIGMAR1 (0.39) | SMN1; SMN2SLC6A2SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL117417 | 0.67 | SMN1; SMN2 (0.40) | SMN1; SMN2SLC6A2SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL1431291 | 0.64 | ALOX5 (0.36) | HTR2AKIF11SMN1; SMN2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079861-B2 | Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| EP-2220052-B1 | CYCLIC UREA INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20100324045-A1 | CYCLIC UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2010-12-23 | — | — | US | disclosed |
| EP-2220052-A1 | CYCLIC UREA INHIBITORS OF 11 -HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009061498-A1 | CYCLIC UREA INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324045-A1 | CYCLIC UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD3B1, HSD11B2 | HTR2A 4119/4885KIF11 3734/4885SMN1; SMN2 2797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.